Payment overview · 2025
General Payments
$104.22
7 reported records · 3 companies
Healthcare provider profile · identity verified
Christopher Robin Bailey, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · VESTAVIA, AL · NPI 1750609350
Verified facts
What the public records show
CMS Open Payments records show Christopher Robin Bailey, M.D. received $104.22 in general payments during 2025 across 7 reported records.
PFIZER INC. accounted for 57.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $59.48 | 57.1% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.45 | 29.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.29 | 13.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $104.22 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $59.48 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $59.48 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $30.45 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.45 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
71 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 283 | 123 |
| Atorvastatin Calcium | Atorvastatin Calcium | 267 | 94 |
| Losartan Potassium | Losartan Potassium | 236 | 91 |
| Gabapentin | Gabapentin | 228 | 47 |
| Montelukast Sodium | Montelukast Sodium | 209 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 200 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 193 | 58 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 181 | 35 |
| Methylprednisolone | Methylprednisolone | 158 | 146 |
| Metoprolol Succinate | Metoprolol Succinate | 152 | 50 |
| Furosemide | Furosemide | 148 | 57 |
| Tramadol Hcl | Tramadol Hcl | 143 | 43 |
| Metformin Hcl | Metformin Hcl | 138 | 56 |
| Lisinopril | Lisinopril | 133 | 61 |
| Glimepiride | Glimepiride | 131 | 50 |
| Carvedilol | Carvedilol | 128 | 53 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 126 | 115 |
| Omeprazole | Omeprazole | 124 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 124 | 21 |
| Azithromycin | Azithromycin | 121 | 113 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 119 | 44 |
| Cefdinir | Cefdinir | 112 | 109 |
| Alprazolam | Alprazolam | 111 | 21 |
| Prednisone | Prednisone | 111 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 42 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 104 | 103 |
| Duloxetine Hcl | Duloxetine Hcl | 102 | 26 |
| Simvastatin | Simvastatin | 98 | 27 |
| Lorazepam | Lorazepam | 95 | 16 |
| Spironolactone | Spironolactone | 95 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 91 | 29 |
| Sertraline Hcl | Sertraline Hcl | 79 | 26 |
| Ezetimibe | Ezetimibe | 78 | 23 |
| Famotidine | Famotidine | 77 | 36 |
| Levofloxacin | Levofloxacin | 75 | 58 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 73 | 37 |
| Eliquis | Apixaban | 71 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 24 |
| Ozempic | Semaglutide | 68 | suppressed |
| Clonazepam | Clonazepam | 67 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 21 |
| Fluconazole | Fluconazole | 66 | 49 |
| Methocarbamol | Methocarbamol | 66 | 24 |
| Potassium Chloride | Potassium Chloride | 64 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 62 | 25 |
| Meloxicam | Meloxicam | 62 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 46 |
| Temazepam | Temazepam | 59 | suppressed |
| Memantine Hcl | Memantine Hcl | 56 | 12 |
| Trazodone Hcl | Trazodone Hcl | 55 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 50 | 14 |
| Pregabalin | Pregabalin | 49 | 16 |
| Farxiga | Dapagliflozin Propanediol | 45 | 11 |
| Allopurinol | Allopurinol | 44 | 17 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 44 | suppressed |
| Celecoxib | Celecoxib | 43 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 20 |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Synthroid | Levothyroxine Sodium | 43 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 42 | 15 |
| Atenolol | Atenolol | 41 | 16 |
| Metronidazole | Metronidazole | 41 | 37 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | 13 |
| Ondansetron Odt | Ondansetron | 40 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Diazepam | Diazepam | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | 14 |
| Baclofen | Baclofen | 36 | suppressed |
| Jardiance | Empagliflozin | 36 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 32 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 30 | 20 |
| Mirtazapine | Mirtazapine | 30 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | 11 |
| Clonidine Hcl | Clonidine Hcl | 25 | 12 |
| Meclizine Hcl | Meclizine Hcl | 25 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | 12 |
| Metformin Hcl Er | Metformin Hcl | 24 | 11 |
| Midodrine Hcl | Midodrine Hcl | 24 | 13 |
| Sucralfate | Sucralfate | 24 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 22 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Testosterone | Testosterone | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 16 |
| Amoxicillin | Amoxicillin | 19 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | 15 |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Minoxidil | Minoxidil | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $104.22 · 7 records | PFIZER INC. | NURTEC ODT, QULIPTA, The Cologuard Plus Collection Kit, UBRELVY, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error